We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Mise au point sur les tumeurs stromales gastro-intestinales (GIST).
- Authors
Pellat, A.; Hautefeuille, V.; Coriat, R.
- Abstract
Gastrointestinal tumours (GIST) are rare mesenchymal tumours of the digestive tract which often arise from the stomach or the small intestine. In 95% of cases they are CD117/KIT and DOG-1 positive in immunochemistry. Various mutations are found in GIST and can influence the prognosis and therapeutic strategy. Among these mutations the most frequent are found in exon 9 and 11 of KIT and in exon 18 of PDGFRa. For localised GIST, the recommended treatment is surgery. Histoprognostic classifications, such as Miettinen's and Lasota, have been developed to evaluate the recurrence risk after surgery and to help in treatment choice. For GIST with an intermediary or elevated risk of recurrence, imatinib should be prescribed in the adjuvant setting for 3 years. Imatinib can also be administered before surgery to reduce tumour volume. For metastatic GIST, imatinib is the first-line treatment.
- Publication
Oncologie (Tech Science Press), 2018, Vol 20, Issue 5/6, p117
- ISSN
1292-3818
- Publication type
Article
- DOI
10.3166/onco-2018-0017